A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. by Remes, Pieter et al.
Remes, P; Selestine, V; Changalucha, J; Ross, DA; Wight, D; de San-
jos, S; Kapiga, S; Hayes, RJ; Watson-Jones, D (2012) A qualitative
study of HPV vaccine acceptability among health workers, teachers,
parents, female pupils, and religious leaders in northwest Tanzania.
Vaccine, 30 (36). pp. 5363-7. ISSN 0264-410X
Downloaded from: http://researchonline.lshtm.ac.uk/298162/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
Vaccine 30 (2012) 5363– 5367
Contents lists available at SciVerse ScienceDirect
Vaccine
jou rn al h om epa ge: www.elsev ier .com/ locate /vacc ine
A  qualitative  study  of  HPV  vaccine  acceptability  among  health  workers,  teachers,
parents,  female  pupils,  and  religious  leaders  in  northwest  Tanzania
Pieter  Remesa,b,1,  Veronica  Selestinea,1, John  Changaluchac,2, David  A.  Rossd, Daniel  Wightb,
Silvia  de  Sanjosée, Saidi  Kapigaa,  Richard  J.  Hayesd,  Deborah  Watson-Jonesa,d,∗
a Mwanza Intervention Trials Unit, National Institute for Medical Research, P.O. Box 11936, Mwanza, Tanzania
b Social and Public Health Sciences Unit, Medical Research Council, 4 Lilybank Gardens, Glasgow G12 8RZ, United Kingdom
c National Institute for Medical Research, P.O. Box 1468, Mwanza, Tanzania
d London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom
e Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Av. Gran Via de l’Hospitalet 199-203, 08908 L’Hospitalet de Llobregat,
Barcelona, Spain
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 15 March 2012
Received in revised form 2 June 2012
Accepted 11 June 2012
Available online 22 June 2012
Keywords:
Human papillomavirus
Vaccine
Acceptability
Schools
Barriers
Tanzania
a  b  s  t  r  a  c  t
Background:  As human  papillomavirus  (HPV)  vaccines  become  available  in  developing  countries,  accept-
ability studies  can help  to better  understand  potential  barriers  and facilitators  of  HPV vaccination  and
guide immunisation  programs.
Methods:  Prior  to a cluster-randomised  phase  IV  trial of  HPV  vaccination  delivery  strategies  in  Mwanza
Region,  Tanzania,  qualitative  research  was  conducted  to assess  attitudes  and  knowledge  about  cervical
cancer  and HPV,  and  acceptability  of  and  potential  barriers  to HPV  vaccination  of  Tanzanian  primary
schoolgirls.  Semi-structured  interviews  (n  = 31) and  group  discussions  (n  = 12)  were  conducted  with  a
total  of  169  respondents  (parents,  female  pupils,  teachers,  health  workers  and  religious  leaders).
Results:  While  participants  had  heard  of cancer  in general,  most  respondents  had  no  knowledge  of cer-
vical cancer,  HPV,  or HPV  vaccines.  Only  health  workers  had  heard  of cervical  cancer  but  very  few  knew
its cause  or  had any  awareness  about  HPV  vaccines.  After participants  were  provided  with  information
about  cervical  cancer  and  HPV  vaccination,  the  majority  stated  that  they  would  support  HPV vaccination
of  their  daughter  to  protect  them  against  cervical  cancer.  Opt-out  consent  for vaccination  was  consid-
ered  acceptable.  Most  preferred  age-based  vaccination,  saying  this  would  target  more  girls before  sexual
debut  than class-based  vaccination.  Potential  side  effects  and  infertility  concerns  were  raised  by  5/14  of
participating  male  teachers.
Discussion:  Reported  acceptability  of  HPV  vaccination  amongst  parents,  teachers  and  other  community
members  was high  in  this  population.  Respondents  stressed  the  need  to  provide  adequate  information
about  the vaccine  to parents,  that  also  addresses  side  effects  and  infertility  concerns.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Human papillomavirus (HPV) vaccines have the potential to
signiﬁcantly reduce the incidence of cervical cancer, the leading
cause of cancer mortality among women in sub-Saharan Africa
[1,2]. Two HPV vaccines have now been approved for use in many
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countries. These provide a high degree of protection against HPV
16/18 infections and associated cervical lesions [3–5]. The World
Health Organisation recommends offering HPV vaccine to girls at
ages 9–14, prior to sexual debut, since the vaccine has highest efﬁ-
cacy if girls have not already acquired HPV [6].
Many high-income countries and some middle-income coun-
tries have started national HPV vaccination programs, either
school-based or on-demand programs, with vaccine coverage
(completion of the 3-dose regimen) ranging from 9% (Greece) to
32% (US) and 76% (UK) [7–10]. In sub-Saharan Africa, two vaccine
demonstration projects have been completed [11,12]; Rwanda has
embarked on a national HPV vaccination programme [13,14], and
Tanzania plans to start a similar programme in 2012. Research in
Africa on HPV vaccine acceptability and delivery is needed to under-
stand how best to deliver this vaccine to adolescent girls among
populations who  have little or no knowledge about cervical cancer,
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Table 1
Number of group discussions and in-depth interviews.
Research method Teachers Parents Female students Health workers Religious leaders
Group discussions 3 (mixed sex) (n = 21F, 14M) 5 (mixed sex) (n = 30F, 24M) 4 (n = 49F) – –
In-depth interviews 1F, 1M 4F, 2M 5F 9F 2 Muslim 7 Christian
F = Female; M = Male.
and may  be suspicious of vaccines that target young women or a
sexually transmitted infection (STI) [15–22].
Between August 2010 and June 2011, in preparation for
a national HPV immunisation program, a phase IV cluster-
randomised trial (NCT01173900) in schoolgirls in Mwanza Region,
Tanzania, was conducted to measure the feasibility, uptake, and
acceptability of two school-based HPV vaccine delivery strategies:
age-based (all girls born in 1998) or class-based (all girls in Year 6
of primary school in 2010) [12]. We  present ﬁndings from a qualita-
tive sub-study conducted before the actual HPV vaccination started
in August 2010. The sub-study’s objectives were to learn what peo-
ple knew about cervical cancer and HPV vaccination, whether they
would ﬁnd HPV vaccination acceptable, and how they viewed vac-
cine delivery and consent procedures. These ﬁndings were used to
improve sensitisation and vaccination procedures within the trial
and to assist preparations for a national HPV vaccination program.
2. Methods
The qualitative sub-study study took place in the two  districts of
Mwanza city and a neighbouring rural district (Misungwi), between
March and August 2010. We  conducted 31 in-depth interviews (IDI)
and 12 group discussions (GD) with a total of 169 respondents,
using a purposive sampling strategy with the purpose of recruiting
particular kinds of respondents, in our case speciﬁc groups or types
of people who would be involved in the different sites of school-
based vaccination. Participants included parents/caregivers, female
students, teachers, religious leaders (seven Christian and two
Muslim), and health workers. Aside from parents in two group dis-
cussions (discussed below), these participants had not received any
project-related sensitisation. A small monetary incentive (equiva-
lent of 3 USD) was provided to adult participants to compensate
them for the time spent during the interview or group discussion.
For interviews with teachers, parents, and pupils, different school
strata were selected: government urban, government rural, and pri-
vate schools. When possible, individuals were recruited from the
three strata (Table 1).
Head teachers assisted in recruiting parents, female students,
and teachers; selection criteria were that these persons would be
involved in the actual vaccination program, either as a parent, a stu-
dent, or a teacher of Year 6 or 12-year-old girls. The girls selected
were asked for written assent after their parents/caregivers gave
their permission. Two group discussions were held with parents
after a cultural dance and drama troupe performed a show on
cervical cancer and HPV. We  chose nine health facilities at ran-
dom, representing rural and urban sites and interviewed one health
worker in each, exploring the following themes: knowledge of cer-
vical cancer and HPV, HPV vaccine acceptability, views on delivery
strategies, decision-making, and other experiences with vaccines
or school-based health services. When respondents demonstrated
no knowledge of cervical cancer, HPV, and/or the HPV vaccine, the
interviewer gave a brief, standard explanation about the planned
HPV vaccination project, and then continued with questions. IDIs
and GDs were recorded, transcribed and translated into English;
the source and/or location of IDI and GD are given after quota-
tions in the main results. Initial coding, which used a list of pre-set
codes based on the research themes with further codes added
that emerged during repeated readings, was  reviewed by a second
researcher who  conducted the ﬁnal analysis.
3. Results
3.1. Population characteristics
The age range of teachers and health workers interviewed was
between 19–51 years and 33–55 years respectively. The 54 stu-
dent respondents had a median age of 12 years and were aged
between 11 and 17 years whilst parents were aged between 18
and 59 years. The majority of parents worked as farmers, ﬁsher-
man  or operate small businesses (e.g., food or vegetable sellers).
Most had completed primary school; a minority (12/60) had com-
pleted secondary school. The religious leaders were aged between
35 and 50 years and came from the following denominations:
Roman Catholic, Anglican, Lutheran, Tanzania Assemblies of God,
African Inland Church, Seventh-Day Adventist, Glory City Church,
and Muslim.
Large scale qualitative research suggests that the median age of
sexual debut is approximately 14 although self-reporting in sur-
veys suggests 16–17 years [23,24]. Primary school enrolment is
generally very high in Tanzania: ofﬁcially, the net attendance ratio
for the primary-school age (7–13 years) population in Mwanza is
73.4% among boys and 76.3% among girls [25]. Part of the main trial
preparations involved a check of pupil attendance records prior to
the start of vaccination; the proportion of pupils absent on any one
day ranged between 9.6 and 19.7% for Year 6 pupils and between
8.1 and 23.5% for all pupils in Years 4–7 [12].
3.2. Knowledge of cervical cancer, HPV, and HPV vaccine
Nine female health workers were interviewed; all but one had
two years of nursing education. All had heard of cervical cancer
but their knowledge was  limited and often inaccurate. When asked
about cervical cancer symptoms, they mentioned vaginal bleeding,
smelly vaginal discharge, or pain during sexual intercourse. Only
two nurses identiﬁed HPV as the cause of cervical cancer. Both
had heard about HPV through preparatory work for an immuno-
genicity and safety trial of the bivalent HPV vaccine in Mwanza
(2009–2010). Another nurse had heard of HPV vaccines on the radio
but could not remember any details. All nurses mentioned a wide
range of, sometimes incorrect, causes of cervical cancer such as
poor genital hygiene, early age at childbirth, frequent childbirth,
abortion, wearing nylon undershorts and insertion of traditional
medicines.
Most parents recognized cancer as a serious, potentially deadly
illness, but knew little about cervical cancer. Two  parents (par-
ticipating in an GD) had heard about it on the radio but did not
remember any details. One 53-year-old father (participating in an
IDI) heard information on the radio but incorrectly thought that
cervical cancer affected women during pregnancy or menstruation,
when poor vaginal cleansing caused women  to contract germs and
then cancer. Four parents (GD) and two  mothers (IDI) had heard
of uterine, but not cervical cancer. No parent had heard about HPV
or the HPV vaccine. The female pupils had heard of cancer in gen-
eral, but none of the 49 girls in GDs had heard about cervical cancer,
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HPV or the HPV vaccine. Similarly, teachers had heard of cancer but
only 1 of 37 knew about cervical cancer, and no teacher had heard
of HPV or the HPV vaccine. One 48-year-old female teacher (IDI)
talked about a family member who had “died of cervical cancer”
but recalled little about the disease. Religious leaders interviewed
knew about cancer in general but nothing of cervical cancer, HPV,
or the HPV vaccine.
3.3. Attitudes towards HPV vaccination
Most respondents welcomed a vaccine that prevents cervical
cancer. Almost all the adults said they would allow their daugh-
ter to be vaccinated since “prevention is better than cure” (female
teacher, GD Malulu). All the girls interviewed said they would like
be vaccinated to avoid a dangerous disease like cervical cancer.
Five (35%) of the 14 male teachers participating in this study (GD
Malulu) dissented and said they would not allow their own  daugh-
ters to be vaccinated. They feared side effects; especially whether
the vaccine would have a potential effect on future reproduction:
“vaccinations in this country that are linked to issues of repro-
duction have had very bad results later on,” or the vaccine could
“disorder and destroy the eggs that a girl has, and reproducing
would be a problem.” The aunt of one student was  suspicious of
the vaccine and had told her: “they are coming to implant cancer in
people. . . they are coming to reduce reproduction” (GD Nyakato).
Most participants trusted the safety of the vaccine, since it had
been explained that the Tanzanian government had approved the
vaccine: “I know the government cannot do something malicious
to children” (parent, GD Mirongo).
All parents stated they would agree to have their daughters vac-
cinated, but some hesitated when confronted with an unknown
infection (HPV), disease (cervical cancer), and vaccine: “That dis-
ease you are talking about, we are completely in the dark about it”
(parent, GD Mkolani), and “The vaccine will have a beneﬁt if it does
not have harmful side-effects” (parent, GD Mirongo).
The ﬁve male teachers (GD, Malulu) who opposed vaccination
also commented that the vaccine might give girls a license to start
sexual activity: “if this is introduced, a person would have the free-
dom to do anything.” A few religious representatives also echoed
this concern but most found the vaccine a ‘good thing’ because it
would protect adolescent girls. No parents thought that the vaccine
would encourage sexual activity among the targeted girls.
Generally, teachers, parents, students, and health workers pre-
ferred age-based vaccination as they believed that this would target
more students who had not yet started sexual activity; choos-
ing students in School Year 6 [where the mean age is 13.9 years
(range 11–22 years)] would include a greater age-range and older
girls who might have started sex. Participants suggested vaccinat-
ing much younger girls: “a ten-year-old child has already started
with sex, the ones who have not started are those aged seven”
(parent, GD Mirongo). A few suggested testing girls’ HPV status
before vaccination. If class-based delivery was to be used, partici-
pants preferred classes lower than Year 6. A few parents preferred
class-based delivery because of simpler logistics, since each girl’s
age would not need to be checked. Other interviewees focused
more on student understanding and preferred 12-year-olds: these
would be “mature enough” to understand the vaccination informa-
tion and could help to “educate parents” (teacher, GD Serengeti);
those in Year 6 would “value” the vaccine more (health worker,
IDI Makongoro).
A few girls and a few parents said that boys might also want
the vaccine, and could feel discriminated against or jealous of the
girls, but the general consensus was that, because cervical cancer
only affects girls, boys would understand if only girls were vacci-
nated. Health workers anticipated that questions from boys could
be resolved by explaining the underlying reasons: “when we  edu-
cated [the boys], they understood” (health worker, IDI Nyakato).
A few respondents asked how out-of-school girls could get the
HPV vaccine. Some parents suggested organising door-to-door vis-
its to identify and vaccinate all girls of a certain age, regardless of
education status. Some religious representatives asked what could
be offered to their wives and adult sisters.
3.4. Previous experiences with school-based/health-centre
vaccinations
The majority of participants were positive about other vac-
cinations, such as for measles, tetanus or polio. They saw that
“when children are vaccinated, they grow up healthy and do not
get that disease” (parent, GD Kayenze). Health workers conﬁrmed
that there was  “much awareness” about infant vaccinations; moth-
ers knew that minor side-effects (a fever, soreness) might occur
post-vaccination (IDI Igoma).
Reactions to a new HPV vaccine being delivered through
primary schools were inﬂuenced by past experiences with
vaccinations and/or school-based health programs. Many par-
ticipants remembered rumours undermining previous vacci-
nation or de-worming campaigns [26–28],  and stressed the
importance of adequate information about the new vac-
cine to reduce the likelihood of rumours undermining future
programmes.
3.5. Health workers’ views on adding HPV vaccination to health
services
When asked about adding HPV vaccination to their workload,
health workers all mentioned familiar concerns about public health
services: insufﬁcient staff serving a large population and lack of
transport. One nurse said, “some places are far away and some of
us have become old” and, with not enough staff, “you might ﬁnd
yourself alone at work for the whole month” (IDI Nyegezi). Health
workers encountered various shortages; of drugs, vaccines, or con-
sumables: “we might lack drugs for two weeks. . . sometimes we
have the drugs but would not have the syringes” (IDI Makongoro).
One nurse summed up ways to alleviate these issues: the
necessary “facilities” for storing vaccine, “enough medicines,”
“motivation [i.e. salary supplements] for those who  go to do the
work,” and training “so that she can administer the vaccine cor-
rectly” (IDI Igoma).
3.6. Views on sensitisation and opt-out consent
All respondents emphasised that parents need appropriate
information and intensive sensitisation about HPV infection and
the new vaccine. Without this, parents would quickly oppose a new
vaccine: “we’d charge you [in court]” (parents, GD Mirongo). All
viewed school-based meetings as an essential sensitisation strat-
egy: “[parents] should get educated like how you [the interviewer]
have come here” (parents, GD Usagara). Teachers said inviting
parents to school meetings was  not always successful. Not all par-
ents may  attend and, even when they did, “you might educate
the wife, but when she gets home to her husband, he refuses”
(health worker, IDI Sangabuye). Some suggested adding radio and
television announcements, so that even those who do not attend
meetings are informed.
Students thought sending letters to parents via students would
work, provided they themselves also received sufﬁcient informa-
tion: “It won’t be difﬁcult [to deliver letters] because many children
will agree to be vaccinated and very few won’t want to get the vac-
cine.” (IDI Buhongwa). Most respondents liked the letter strategy
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but some teachers cautioned about relying on written information:
not all parents know how to read.
Most teachers, parents, and students said it was  necessary to
get parental permission, but not necessary to ask each parent for
individual written consent. Most interpreted consent as a process
whereby parents would be informed about the school-based vac-
cination programme, either by letters, meetings, by the targeted
child, or other types of announcements (like radio or television);
parents could refuse to allow their child to be vaccinated by making
this known to the school or by keeping the child home on vac-
cination day. A few teachers (GD Ng’ombe) suggested that active
consent should be required from parents, or that parents should
accompany their daughter on the day of vaccination to ensure
that parental wishes are respected. Teachers feared parents might
threaten them at school, as happened during past health pro-
grammes, or take them to court. Some health workers suggested
that teachers might have coerced their students during prior vac-
cination campaigns: “when we go to administer a vaccine, we ﬁnd
the teachers have gathered the girls, and they are standing by the
door with a stick, . . .”  (health worker, IDI Pasiansi).
Some parents, teachers and students said that if a student has
sufﬁcient understanding and wants to be vaccinated, she should get
the HPV vaccine even if her parent(s) refused. “The child ought to be
given the vaccine because it’s for her beneﬁt, provided she’s willing
and has got sufﬁcient education. If the parent isn’t willing, it’s the
right of the child to get it” (teachers GD Serengeti); “I should be vac-
cinated because I’m the one who’ll contract the disease” (student,
IDI Nyamhongolo).
Health workers were accustomed to giving infant and child
vaccinations without parental consent. With nationally-mandated
vaccinations, health workers go to schools, inform the teachers,
and on vaccination day, inform and vaccinate the children. These
are vaccines that “the community knows and understands [to not
be] harmful” (health worker, IDI Igoma). Most health workers felt
that, if the government mandates HPV vaccine as part of the school
vaccination program and the community has been ‘educated’, this
should be sufﬁcient. Two (of nine) health workers said children
should not be vaccinated if their parents refuse, but health workers
should try to convince these parents of the vaccine’s beneﬁt. Most
health workers said that if the child understands and wants the
vaccine, she should be vaccinated: “what I aim at is to save the life
of the child, not the parent” (IDI Nyegezi). Another said: “A child is
yours when she’s in the womb.  Once she’s born, she belongs to the
government . . . it can protect her” (IDI Butimba).
4. Discussion
We found that teachers, parents, pupils and health workers
interviewed in our qualitative sub-study had limited or no knowl-
edge about cervical cancer, HPV, and the HPV vaccine. Generally,
most welcomed a vaccine to prevent cervical cancer and most
parents said they would agree to have their daughter vaccinated
although some adopted a “wait and see” approach. Most had a
strong belief that vaccines prevent diseases. Our ﬁndings are simi-
lar to formative research results by PATH in Uganda, Peru, Vietnam
and India prior to HPV vaccination [29,30], and recent studies on
vaccine acceptability in Ghana, Botswana, Kenya, and South Africa
[31–34]. In a study amongst 147 Kenyan women seeking health ser-
vices there was little knowledge about either cervical cancer or the
HPV vaccine [31]. Findings were similar in South African antena-
tal attenders [34]. In Botswana, awareness of cervical cancer was
higher amongst many adults (mostly female) but again, few had
heard of HPV vaccine [32]. In a Ghanaian study among 264 women,
ages 18–65, where most had received higher education after sec-
ondary school, 87% of study participants had heard about cervical
cancer and 40% about the HPV vaccine [33]. Despite variability in
cancer and vaccine awareness, in all of these sub-Saharan studies,
the majority of the women  were willing to vaccinate their child.
Anti-fertility rumours, raised as a potential issue for the vaccine
in our study and the study in Uganda, are widespread in Africa in
relation to vaccines and health-related products and reﬂect under-
lying suspicions about public health interventions [35,36].  People
may  object to imported, foreign drugs and new medical interven-
tions; knowing that the HPV vaccine has already been administered
in Africa and is approved by the Tanzanian government was thought
to be persuasive by many respondents.
Issues of power and control over health emerged in the dis-
cussions about opt-out consent. Health workers saw public health
actions as mandatory and considered that individual parent con-
sent was not a necessary part of national immunisation policy,
although provision of information to parents and communities was
important. This was  also stressed by other respondents. In Mwanza,
parents wanted to be involved in the decision-making process but
the consensus was that opt-out consent was  acceptable, and there
was considerable support for a girl’s right to be vaccinated, even
if parents refused their consent. Uganda’s pilot HPV vaccination
program also used a similar opt-out approach [20]. No parents in
our study reported concerns that the vaccine might stimulate sex-
ual activity, a concern that has sometimes emerged in high-income
countries [37,38].
Many respondents among the different groups (teachers, par-
ents, health workers, religious representatives, female pupils)
stated that parents should be given adequate information about the
vaccine and cervical cancer, and that a school meeting would be an
essential strategy to reach the parents. People were eager to learn
about the HPV vaccine. Religious leaders reported that this was the
ﬁrst time that staff from a health programme had come to discuss a
health intervention with them, and that they would discuss cervical
cancer and HPV vaccination with their congregations.
Limitations of the qualitative sub-study included the fairly small
purposive samples and the fact that, in schools, a teacher selected
the parent, student and teacher participants for GDs who  might
have been the most accepting of new health interventions. How-
ever, the interviewer then selected IDI participants from the groups.
These included several teachers who opposed vaccination, parents
who asked critical questions, and female students who stated they
would defy parental wishes in terms of accepting vaccine.
In USA, beliefs about the safety of vaccines, likelihood of HPV
infection, as well as doctor’s recommendations, have been associ-
ated with increased HPV vaccine acceptability [39–41].  In Mwanza,
anti-fertility rumours, experience of previous school-based health
interventions for girls, and lack of knowledge about cervical can-
cer in targeted communities, including amongst health workers,
could be a potential challenge to vaccine uptake. It will therefore
be essential that correct information about HPV vaccination is pro-
vided to parents, pupils, community members and key personnel
(teachers, health workers) to help prevent the emergence and/or
spread of rumours before and during HPV vaccination programmes.
In light of the recent price reduction of the Gardasil® vaccine
for low-income countries [42], many African governments may
now consider adding the HPV vaccine to their national programs.
Our research identiﬁed key issues related to vaccine acceptability
and allowed adaptation of communication materials for the sub-
sequent HPV vaccination demonstration project in Mwanza. Our
ﬁndings also informed health worker training on issues related to
obtaining parental agreement to vaccinate daughters, and rumour
management. For a successful national programme on cervical can-
cer prevention, health workers should acquire additional training
on the disease and prevention strategies. Adequate sensitisation,
through school and/or community meetings and mass media,
of all relevant populations, including parents, students, teachers,
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community and religious leaders will be essential for the success
of a national HPV vaccination campaign in Tanzania.
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